Growth Hormone · 2mg × 10 vials
In plain terms: CJC-1295 With DAC is a research compound - injectable, long-acting and well studied.
CJC-1295 With DAC is the long-acting variant of CJC-1295: the same DPP-IV-resistant GHRH 1-29 analog (tetra-substituted at positions 2, 8, 15, and 27 to block enzymatic cleavage) with one extra modification, a maleimido-propionyl-lysine appended at the C-terminus. That maleimide tether is the "Drug Affinity Complex" (DAC). On injection, the maleimide group covalently binds the free cysteine-34 thiol on circulating human serum albumin, effectively turning each CJC-1295 molecule into an albumin-tethered passenger. Albumin has a half-life of roughly 19 days, so the drug-albumin complex rides that clearance curve and the active GHRH analog stays in circulation for 6 to 8 days instead of 30 minutes. The result is sustained occupation of the GHRH receptor on pituitary somatotrophs for the better part of a week from a single SubQ shot. Teichman 2006 (JCEM) is the landmark human PK/PD paper: a single dose of CJC-1295 With DAC produced 2-10x baseline GH elevation and 1.5-3x IGF-1 elevation that remained statistically significant out to 14-28 days in healthy adults.
The clinically important consequence is the GH curve shape, not just the duration. Native GHRH and CJC-1295 No DAC produce discrete, short pulses that decay within an hour or two, mimicking the body's natural pulsatile GH rhythm. CJC-1295 With DAC produces a "GH bleed": continuously elevated GH and IGF-1 across the entire dosing interval, with no return to baseline between shots. Pulsatility is preserved at small amplitude on top of this elevated tonic baseline, but the dominant pattern is sustained elevation rather than discrete pulses. This matters because hepatic IGF-1 production and somatotroph signaling are tuned to pulse pattern; continuous GH exposure drives more insulin resistance, more receptor downregulation over time, and a less physiologic IGF-1 curve than pulsatile elevation does. The 2006 Teichman trial also reported that GH binding protein (a marker of GH receptor downregulation) climbed at higher doses, and one trial site experienced an unexpected death that did not get linked to drug action but contributed to a long pause in clinical development. CJC-1295 With DAC has not been advanced into a Phase 3 program by any sponsor since that pause; modern use is almost entirely research / community / clinic, not licensed therapeutic.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
Standalone With DAC is the "weekly-only injection burden tolerable" entry point. Customer profile is someone who has explicitly said daily injections are a compliance dealbreaker, or who is needle-averse, or who travels in a way that makes daily peptide protocols logistically impossible. Effects are real but the felt response is muted vs the paired CJC+Ipa kit because there's no GHRP driving the actual pulse, just elevated GHRH baseline. Customers who expect a strong felt response from standalone With DAC often interpret the absence of "feeling something" as the compound not working when really it's the absence of a ghrelin-receptor agonist they're noticing. Sleep improvement is usually the first signal at 1-2 weeks; lean fullness and skin quality at 6-10 weeks.
The intermediate band is where the "pair with daily ipamorelin to restore pulsatility" convention kicks in. Pure With DAC alone produces a GH bleed; layering daily ipamorelin on top gives back the pulse component the DAC variant lacks. This is the most physiologically defensible way to run With DAC, and most experienced community users converge on this pattern by their second cycle. The pre-bed ipamorelin shot also delivers the slow-wave-sleep GH stack that customers feel most clearly.
Advanced With DAC is rare in Jordan's customer base. The customer profile that defaults to With DAC at beginner level (low-frequency-injection preference) doesn't usually escalate into advanced multi-shot daily ipamorelin pairing - at that point they've effectively rebuilt the paired CJC+Ipa kit protocol with a different CJC half. Advanced users who want strong GH effects almost always switch to HGH or the paired No DAC kit rather than escalating With DAC.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
landmark CJC-1295 With DAC PK/PD paper, 5.8-8.1 day half-life, 2-10x GH elevation, 1.5-3x IGF-1 elevation, GH binding protein creep at higher doses, unexplained trial site death that contributed to clinical development pause
Read study ↗PubMedIonescu M, Frohman LA, Pulsatile vs continuous GH secretion after CJC-1295, JCEM 2006pulsatility-vs-bleed framework comparing the two CJC variants
Read study ↗PubMedSackmann-Sala L et al, A mechanistic view of growth hormone signaling pathwaysGHRH receptor pharmacology and why pulse vs continuous signaling produces different downstream IGF-1 curves
Read study ↗PubMedJette L et al, hGRF1-29-albumin bioconjugates activate GHRH receptor, 2005, PMID 15976377original albumin-bioconjugate mechanism paper explaining DAC chemistry
Read study ↗Clinical guidelinesCJC-1295 With DAC complete research guide, Your Peptide Brand 2026synthesis of pharmacokinetics, RCT data, DAC mechanism
Read study ↗Clinical guidelinesCJC-1295 With DAC vs Without DAC pharmacokinetic comparison, Particle Peptidesbest mechanistic side-by-side comparison
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Hand/foot tingling: more pronounced and longer-lasting than with No DAC because the fluid pressure accumulates continuously rather than resolving between pulses. Most users report it lasts the entire first 3-4 weeks of a cycle vs 2 weeks on No DAC.
Water retention / puffy face and hands: noticeably worse than No DAC in side-by-side user reports. The "GH bleed" pattern is what drives this. Community fix: lower dose for one week, increase water and reduce sodium.
Better sleep within 3-7 days: present but less dramatic than No DAC / paired kit because the sleep effect is partly tied to the pre-bed pulse stacking on top of the natural slow-wave-sleep GH pulse, and With DAC's elevated tonic baseline reduces the relative amplitude of that endogenous pulse.
IGF-1 elevation that holds: blood work in community reports shows IGF-1 staying elevated for 10-14 days from a single 2 mg shot. This is the strongest selling point of With DAC vs the alternatives, and what attracts customers whose explicit goal is IGF-1 elevation rather than pulsatile GH support.
Fasting glucose creep: real and reported, especially at 2 mg/wk or twice-weekly dosing. Users with continuous glucose monitors describe fasting glucose climbing 5-10 mg/dL by week 4-6, settling once cycled off. T2D / prediabetic users should monitor.
Convenience: this is the most-cited positive in community reports. Customers who switched from daily No DAC or paired kit to weekly With DAC almost universally describe the compliance win as the main reason they stay on it, even at the cost of milder felt effects.
Route: SubQ (subcutaneous injection into abdomen or outer thigh fat)
Injection site: abdomen pinch (around the navel, 2 inches out) or outer thigh; rotate sites each shot, fresh insulin syringe each time. Larger draw volume means most users prefer abdomen over thigh for comfort.
Storage: refrigerated, ~30 days after reconstitution. Unreconstituted vials stable at room temp short-term, refrigerate for long-term storage. Don't freeze reconstituted vials.
Notes: The fasted-window rule is much less important with With DAC than with No DAC. Because GH is elevated continuously for 6-8 days from a single shot, blunting the immediate pulse with food at injection time has minimal effect on the overall AUC. Most users still inject pre-bed for sleep-pulse alignment and habit consistency, but the "2 hours fasted before, 30 min after" discipline that matters for No DAC and the paired kit is not load-bearing here. Standard schedule is once or twice weekly, fixed days (e.g., Mon or Mon/Thu), any time of day. Compatible in the same syringe with most non-GH peptides; do not co-inject with another GHRH analog (sermorelin, tesa, No DAC) at the same time, redundant receptor activity.